* VectivBio Holding AG VECT.OQ VECT.O is expected
to report
results on April 19.
* The Basel Basel-stadt-based company is expected to report
revenue of $4.313 million, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for VectivBio Holding
AG is
for a loss of 56 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for VectivBio
Holding
AG is $22, above its last closing price of $8.60.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.66
Sep. 30 2021 -0.61
Jun. 30 2021 -0.51
Mar. 31 2021 -0.57
This summary was machine generated April 17 at 11:10 GMT. All
figures in US dollars unless otherwise stated